MTAA
NEXI
Market cap4.74bUSD
Jun 18, Last price
3.52EUR
1D
-0.56%
1Q
23.94%
IPO
-58.59%
Name
Nexi SpA
Chart & Performance
P/E
24.70
P/S
0.66
EPS
0.14
Div Yield, %
7.10%
Shrs. gr., 5y
17.23%
Rev. gr., 5y
30.67%
Revenues
6.29b
+6.63%
Net income
167m
P
CFO
974m
+7.93%
Dividend
May 18, 20260.3 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As a clinical-stage biotechnology firm, NexImmune, Inc. is dedicated to developing potentially curative treatments for individuals battling cancer and severe immune disorders. Their approach leverages T cell immunotherapies, based on their exclusive Artificial Immune Modulation (AIM) nanoparticle technology platform. The company's pipeline includes NEXI-001, an allogeneic cell therapy currently undergoing Phase I/II clinical trials for acute myeloid leukemia; NEXI-002, an autologous cell therapy also in Phase I/II studies, targeting relapsed or refractory multiple myeloma; and NEXI-003, an early-stage candidate designed to combat HPV-associated malignancies. NexImmune, Inc. was established in 2011 and is based in Gaithersburg, Maryland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||